By Fineline Cube WuXi Biologics (HKG: 2269) announced on June 16, 2026, a comprehensive Contract Development, Research, and Manufacturing Organization (CDRMO) collaboration with CANbridge Pharmaceuticals (HKG: 1228). Under the agreement, CANbridge will procure end-to-end CDRMO services from WuXi Biologics through December 31, 2028.
Partnership Framework | Key Terms
| Component | Details |
|---|---|
| Parties | WuXi Biologics (HKG: 2269) and CANbridge (HKG: 1228) |
| Agreement Type | CDRMO (Contract Development, Research, and Manufacturing Organization) |
| Effective Date | June 16, 2026 |
| Term | Through December 31, 2028 |
| Services Scope | Comprehensive biologics development and manufacturing |
CDRMO Services Portfolio
The agreement encompasses WuXi Biologics’ full suite of integrated services, including:
- Process development – Upstream and downstream process optimization
- Formulation development – Drug product formulation and stability studies
- Clinical manufacturing – GMP production for clinical trial materials
- Commercial manufacturing – Large-scale commercial supply capabilities
- Storage and logistics – Cold chain storage and distribution services
- Quality testing – Comprehensive analytical and quality control testing
Strategic Rationale
For CANbridge
- Secures long-term manufacturing capacity through 2028
- Gains access to WuXi Biologics’ integrated CDRMO platform
- Enables focus on clinical development and commercialization while outsourcing complex manufacturing operations
- Supports advancement of CANbridge’s pipeline of rare disease and oncology therapeutics
For WuXi Biologics
- Expands strategic partnership portfolio with innovative biotech companies
- Utilizes existing manufacturing capacity across global facilities
- Demonstrates continued demand for integrated CDRMO services in Asia-Pacific biopharma market
- Strengthens position as preferred partner for Hong Kong-listed biotech companies
Market Context
This partnership reflects the growing trend of asset-light biotech companies leveraging specialized CDRMO providers to accelerate drug development timelines while managing capital expenditure. With over $15 billion invested in biologics manufacturing capacity globally since 2020, WuXi Biologics continues to capitalize on the outsourced biologics manufacturing market, which is projected to reach $25 billion by 2028.
The three-and-a-half-year term provides CANbridge with manufacturing security through critical late-stage development and potential commercial launch phases, while offering WuXi Biologics predictable revenue streams and facility utilization.
Forward-Looking Statements
This brief contains forward-looking statements regarding business partnerships, service agreements, and market trends. Actual results may differ due to risks including regulatory changes, operational challenges, and market dynamics.-Fineline Info & Tech